ImmunOs Therapeutics AG raises US$11m in Series C financing - European Biotechnology
ImmunOs Therapeutics to use funds for completing Phase Ia dose escalation study of IOS-1002, a multifunctional immunotherapy for advanced solid tumors, in combination with pembrolizumab. IOS-1002 targets LILRB1, LILRB2, and KIR3DL1 to activate both innate and adaptive immune cells, aiming to enhance existing immunoncological treatments.
Reference News
ImmunOs Therapeutics AG raises US$11m in Series C financing - European Biotechnology
ImmunOs Therapeutics to use funds for completing Phase Ia dose escalation study of IOS-1002, a multifunctional immunotherapy for advanced solid tumors, in combination with pembrolizumab. IOS-1002 targets LILRB1, LILRB2, and KIR3DL1 to activate both innate and adaptive immune cells, aiming to enhance existing immunoncological treatments.